Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

The company defends its cancer strategy, and says it's not a me-too developer.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.

Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?